Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal study of recombinant human Alkaline Phosphatase (recAP) in patients with Acute Kidney Injury

Trial Profile

A pivotal study of recombinant human Alkaline Phosphatase (recAP) in patients with Acute Kidney Injury

Planning
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2018

At a glance

  • Drugs Alkaline phosphatase (Primary)
  • Indications Acute kidney injury
  • Focus Registrational; Therapeutic Use
  • Sponsors AM-Pharma
  • Most Recent Events

    • 31 Oct 2018 New trial record
    • 24 Oct 2018 According to an AM-Pharma media release, the company is preparing for this pivotal study to confirm the STOP-AKI study results.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top